CDKN1A KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon2.
Images
Key facts
- Cell type
HCT116
- Species or organism
Human
- Tissue
Colon
- Knockout validation
Sanger Sequencing, Western blot
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon2.
Alternative names
CAP20, CDK-interacting protein 1, CDKI, CDKN1, CDKN1A, CDN1A_HUMAN, Cyclin Dependent Kinase Inhibitor 1A, Cyclin-dependent kinase inhibitor 1, Cyclin-dependent kinase inhibitor 1A (P21), Cyclin-dependent kinase inhibitor 1A (p21, Cip1), DNA Synthesis Inhibitor, MDA-6, Melanoma differentiation-associated protein, Melanoma differentiation-associated protein 6, P21 protein, PIC 1, SDI1, SLC12A9, WAF1, Wild type p53 activated fragment 1 (WAF1), Wildtype p53-activated fragment 1, p21CIP1, p21Cip1/Waf1, p21WAF
What's included?
Recommended products
CDKN1A KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon2.
Alternative names
CAP20, CDK-interacting protein 1, CDKI, CDKN1, CDKN1A, CDN1A_HUMAN, Cyclin Dependent Kinase Inhibitor 1A, Cyclin-dependent kinase inhibitor 1, Cyclin-dependent kinase inhibitor 1A (P21), Cyclin-dependent kinase inhibitor 1A (p21, Cip1), DNA Synthesis Inhibitor, MDA-6, Melanoma differentiation-associated protein, Melanoma differentiation-associated protein 6, P21 protein, PIC 1, SDI1, SLC12A9, WAF1, Wild type p53 activated fragment 1 (WAF1), Wildtype p53-activated fragment 1, p21CIP1, p21Cip1/Waf1, p21WAF
Key facts
- Cell type
HCT116
- Species or organism
Human
- Tissue
Colon
- Knockout validation
Sanger Sequencing, Western blot
- Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon2.
- Disease
Carcinoma
- Concentration
Properties
- Gene name
CDKN1A
- Gene editing type
Knockout
- Gene editing method
CRISPR technology
- Knockout validation
Sanger Sequencing, Western blot
- Zygosity
Homozygous
Quality control
- STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
EU: 1 US: 1
- Adherent/suspension
Adherent
- Gender
Male
Storage
- Shipped at conditions
Ambient - Can Ship with Ice
- Appropriate long-term storage conditions
-20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- Activity summary
The p21 protein also known as CDKN1A is an important regulator of cell cycle progression. It acts as a cyclin-dependent kinase inhibitor where it binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes. The molecular weight of p21 is approximately 21 kDa. Cellular expression of p21 is diverse; it occurs in various tissues reflecting its broad role in maintaining cell cycle control. This protein's expression level is often assessed using techniques such as p21 western blotting p21 ELISA and p21 IHC staining.
- Biological function summary
P21 plays a critical role in cell cycle regulation and DNA damage response. It associates with the p53 tumor suppressor protein forming an essential part of the p53 signaling pathway under stress conditions. p21 arrests cells in G1 phase allowing DNA repair or leading to cellular senescence. Through these mechanisms p21 integrates signals from stress and damage emphasizing its importance as a mediator in cellular checkpoint control.
- Pathways
P21 is closely involved in the p53 and the Transforming Growth Factor-beta (TGF-β) signaling pathways. This integration helps in transmitting growth-inhibitory signals. p21 interacts with proteins such as p53 and cyclins ensuring precise regulation of the cell cycle and growth arrest when necessary. Triggered by p53 activation p21 contributes to preventing undisturbed cell proliferation acting as a safeguard against tumor formation.
- Associated diseases and disorders
P21's deregulation associates with cancer and age-related diseases. Its impairment is a common feature in many cancers often linked with defects in the p53 pathway. Reduced p21 expression can contribute to unchecked cell division and tumor progression. Moreover in age-related diseases p21's role in promoting cellular senescence connects it with degenerative conditions. The intricate relationship between p21 and proteins such as p53 and cyclins highlights its potential as a therapeutic target for these disorders.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Western blot - Human CDKN1A knockout HCT116 cell lysate (ab256870)
Lane 1: Wild-type HCT116 cell lysate (20μg)
Lane 2: CDKN1A knockout HCT116 cell lysate (20μg)
Lanes 1- 2: Merged signal (red and green). Green - Anti-p21 antibody [EPR3993] ab109199 observed at 20 kDa. Red - loading control Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa.
Anti-p21 antibody [EPR3993] ab109199 Anti-p21 antibody [EPR3993] was shown to specifically react with p21 in wild-type HCT116 cells in western blot. Loss of signal was observed when knockout cell line Human CDKN1A knockout HCT116 cell line ab266860 (knockout cell lysate ab256870) was used. Wild-type and p21 knockout samples were subjected to SDS-PAGE. Membrane was blocked for 1 hour at room temperature in 0.1% TBST with 3% non-fat dried milk. Anti-p21 antibody [EPR3993] ab109199 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.All lanes: Western blot - Anti-p21 antibody [EPR3993] (Anti-p21 antibody [EPR3993] ab109199) at 1/1000 dilution
Lane 1: Wild-type HCT116 cell lysate at 20 µg
Lane 2: CDKN1A knockout HCT116 cell lysate at 20 µg
Performed under reducing conditions.
Predicted band size: 18 kDa, 197 kDa, 36 kDa, 47 kDa, 72 kDa, 84 kDa
Observed band size: 150 kDa, 20 kDa, 40 kDa, 45 kDa, 47 kDa
Sanger Sequencing - Human CDKN1A knockout HCT116 cell lysate (ab256870)
Homozygous: 1 bp insertion in exon2
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com